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ABSTRACT
Introduction: Pompe’s disease is a metabolic 
myopathy caused by a deficiency of the 
enzyme alpha-glucosidase. Patients with late-
onset Pompe’s disease have progressive muscle 
weakness, which also affects pulmonary 
function. Since the advent of specific treatment 
for Pompe’s disease, enzyme replacement 
therapy with alpha-glucosidase, the prognosis 
of the disease has changed. Methods: We report 
the case of the first patient treated in Spain with 
home therapy, and the effects on her clinical 
status of a reduction in treatment frequency. 
Results: A worsening was seen in the patient’s 
neuromuscular assessment on different scales, 
after two discontinuations during the patient’s 
usual administration frequency. Conclusion: It 
is essential to keep an adequate administration 
schedule to maintain the clinical benefits of 
enzyme therapy. 
Keywords: alpha-glucosidase replacement 
enzyme; maltase acid deficiency; neuromuscular 
disease; Pompe’s disease 
INTRODUCTION
Lysosomal storage diseases (LSD) are caused by 
congenital metabolic errors and are characterized 
by a deficiency of a given enzyme within the 
lysosome, resulting in progressive accumulation 
of substances causing a storage disease. The 
combined prevalence of these diseases is one 
per 7700 live births, although there is variability 
depending on the type of disease.1
Pompe’s disease (PD) is an LSD, and results 
from the deficiency of acid alpha-glucosidase 
(GAA), the enzyme responsible for degradation 
of glycogen to glucose. It was first described in 
1932 by the Dutch pathologist J.C. Pompe.2
It is also known as maltase acid deficiency, 
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glycogen storage disease type II, or glycogenosis 
type II. It is inherited in an autosomal recessive 
manner.3 It is a disease with a continuous and 
variable spectrum of symptoms. The data on 
the combined incidence of all clinical subtypes 
is one per 40,000 births.4
The accumulation of glycogen primarily 
affects muscle tissue, causing progressive 
musculoskeletal degeneration, respiratory 
impairment, and involvement of the heart 
muscle in children in particular.5,6 It presents 
with a variable clinical spectrum in terms of age 
of onset, progression, and organ involvement. 
Two forms of onset are distinguished: early 
(infantile) and late onset. When onset is prior 
to 12 months of age, the first symptoms usually 
occur in the first 3 months. Death usually occurs 
before 1 year of age.7 In the late onset forms, 
the clinical picture resembles that of muscular 
dystrophy. Motor delay occurs due to weakness 
in proximal limb muscles and the involvement 
of respiratory muscles.8 In adults, symptoms 
may start from the 2nd to the 6th decade of life 
as progressive myopathy predominantly in the 
proximal pelvic muscles.9,10 Disease progression 
leads to the use of assisted ventilation, and a 
wheelchair due to muscle weakness.
In 2006, both the Food and Drug 
Administration and the European Medicines 
Agency approved the marketing of recombinant 
human GAA (rh-GAA) as specific treatment 
for PD. Administration of treatment is by 
intravenous infusion every 2 weeks, and is 
lifelong. As it is a chronic disease, the patient 
must go to a center where the drug can be 
administered, thus becoming dependent on the 
health system. 
Strict adherence to the treatment schedule 
and adequate dosing becomes essential in these 
patients to optimize the results, however, there 
is no evidence as to how inadequate dosing may 
affect the clinical symptoms of the patient. This 
article describes the case of a female patient with 
PD who experienced worsening of her clinical 
condition after suppression of two doses of her 
treatment. This is also the first case in Spain of a 
patient who received home therapy with this drug.
REPORT
The case was a 39-year-old woman, with no 
relevant family history, who had been operated 
on three times in childhood for bilateral 
clubfoot. Informed consent was obtained. 
From 14 years of age, the patient experienced 
progressive muscle weakness in the four 
extremities, predominately proximal, and 
more significant in the legs, making it difficult 
for her to climb stairs, rise from the floor, and 
run. At 18 years of age, weakness manifested in 
the arms and she started to experience dyspnea 
on exertion. 
At 20 years of age, a biopsy of the biceps 
muscle was performed, revealing a vacuolar 
myopathy with glycogen accumulation, increased 
phosphatase acid activity, and breakdown of 
muscle fibers; changes consistent with myopathy 
due to maltase acid deficiency or PD. Examination 
revealed tetraparesia of a predominantly proximal 
nature with scapular winging. An electromyogram 
showed a myopathic pattern. Transaminases and 
creatine phosphokinase levels were elevated. 
Cardiac function appeared normal, and 
pulmonary function tests showed a vital capacity 
of 32% with a muscular inspiratory pressure of 
16 cm H2O and an O2 saturation of 96%.
At 23 years of age, she required the use of 
a wheelchair to move due to her inability to 
stand or walk. At 26 years of age, treatment was 
started with noninvasive assisted ventilation 
via a nasal mask during sleep. At this time, the 
vital capacity was 600 cc (20%) and blood gases 
showed pO2 67 mmHg and paCO2 58 mmHg. 
At 31 years of age, a gastrostomy was performed, 
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given her difficulties for oral nutrition. At this 
point, her dependence on the ventilator was 
virtually total. 
In January 2005, she started replacement 
therapy with rh-GAA with a dosing regimen 
of 20 mg/kg every 15 days (2 weeks), with no 
adverse reactions. The neuromotor and functional 
assessment before starting replacement therapy 
were the most significant findings (using the 
Muscle Strength Scale [Medical Research Council 
Scale]):11,12 neck flexors-extensors - 3/5, trunk 
muscles - 0 (does not control trunk), right arm: 
proximal muscles - 0/5, elbow flexors - 1/5, carpal 
bone extensors - 3/5, finger flexors - 3/5, thumb 
approximator - 2/5. Rest of hand muscles - 0/5. Left 
arm: overall proximal muscles - 0/5, elbow flexors-
extensors - 0/5, carpal bone extensors - 3/5, finger 
flexors - 2/5. Rest of hand muscles - 0/5. Right leg: 
hip flexors - 1/5, hip approximators - 1/5, knee 
extensors - 0/5, knee flexors - 1/5, finger flexors 
- 2/5. Rest of muscles - 0. Left leg: hip flexors - 1/5, 
hip approximators - 2/5, knee extensors - 0/5, 
knee flexors - 1/5, finger flexors - 2/5. Rest of 
muscles - 0. The patient had a Functional 
Independence Level (Functional Independence 
Measure [FIM] scale) score of 53 out of 126. 
She had a Walton & Gardnerd-Medwin Scale13 
grade of 9 (out of 10). The patient was dependant 
on a ventilator for virtually 24 hours a day.
Four months after the start of treatment, 
new assessments were performed on the patient, 
showing the changes from baseline (described 
in Table 1). The most notable were the ability to 
remain upright for over 30 minutes, the improved 
functionality of the right hand, and particularly 
the ventilator-free time (over 7 hours), and 
recovery of oral feeding (Images 1 and 2).
These results remained unchanged until 
March 2009 when, after decreasing the 
administration schedule to 20 mg/kg every 
30 days for 2 months because of a supply 
problem, a clear regression was noted in the 
previously observed positive clinical findings 
(Table 1). There was no intercurrent infection 
or any other situations that could explain 
this worsening.
Table 1. Comparison of efficacy between dosing schedules.
Baseline 20 mg/2 weeks 20 mg/month
Neck flexors-extensors 2/5 3/5 2/5
Trunk muscles 0 Stay upright  
(30 mins)
0
Proximal arm muscles 0/5 0/5 0/5
Right elbow extensors 1/5 2/5 1/5
Right hand 2/5 4/5 3/5
Proximal leg muscles 0/5 0/5 0/5
Hours without assisted ventilation 0 7 3













FIM=Functional Independence measure scale.
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After reinitiation of treatment with a 
2-weekly dosing schedule, the results of tests 
were in the range of the values prior to treatment 
interruption, with the patient recovering the 
ventilator-free time of up to 7 hours. Clinical 
and functional conditions of this patient have 
continuously been stable since then, up to the 
present day.
DISCUSSION
The importance of adequate treatment is 
reflected in the case reported here. The 
efficacy of rh-GAA treatment has been shown 
in different trials with the drug. In the phase 
2 trial, it was shown that children treated 
with rh-GAA had a survival rate of 73% 
versus 37% in the control group. This trial 
also showed improvement in weight gain and 
height. Early treatment improved results.14 
In a phase 3 trial in patients aged 5 to 15 years, 
increases were seen in respiratory function 
and distance walked.15,16 There is very recent 
data on the efficacy of replacement therapy,17
however, there are still many unknowns on the 
importance of the dose and dosing intervals of 
the enzyme. It is also important to emphasize 
the fact that patients can obtain great benefits 
if they are treated at home. 
The main limitation of the study is that it 
shows the experience of only one patient who 
is much more severely affected by the disease 
(Images 1 and 2) than the patients included in 
many other reported studies.
In the case of this patient, it is clear that 
the organic damage caused until initiation 
of treatment made it difficult to obtain a very 
marked improvement, but the recovery of 
functional control of the trunk, substantial 
improvement in ventilator-free time, and 
Image 1 and 2. Patient affected by Pompe’s disease after 6 months of treatment with enzyme replacement therapy. 
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increased strength and functionality of the 
right arm has allowed her a certain degree of 
independence, making it possible for her to 
partially feed herself orally.
Preliminary data from the study carried out 
in adult patients to establish efficacy and safety 
showed a clinical benefit in the test of distance 
walked in 6 minutes and stabilization of lung 
function.17 These preliminary data showed the 
importance of treatment, compared with the 
historical cohort without treatment.
CONCLUSION
What is relevant in this case is not only the 
efficacy of treatment with the enzyme and the 
benefits for the patient and family to be treated 
at home, but that despite being a patient with 
a substantially worse baseline status than the 
patients included in the different reported 
studies, the results were relevant for the 
autonomy of the patient (Images 1 and 2). 
It is also essential that dosing is adequate, 
as was shown in this patient, who recovered 
the levels of autonomy lost after reducing the 
frequency of treatment. Therefore, it can be 
concluded that maintaining dosing frequency is 
important for achieving optimum results, even 
in patients in whom the disease is severe.
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